Document is current
Any future updates will be listed below
-
Authors
Salih, Mohammed A. M.
Salem, Mohamed M. A. E. L.
Shahid, Muhammad Ali
Elrewey, Hussein A. S.
Williamson, Ritchie
Kantamneni, Sriharsha https://orcid.org/0000-0002-3750-9447
-
Funding
Funding for this research was provided by:
This study was funded partly by the Prisoner of Conscience Appeal Fund and supported by Brad-ATTAIN, University of Bradford
- License Information
-
More Information
Article History
Received: 27 August 2025
Accepted: 29 December 2025
First Online: 30 January 2026
Declarations
:
: All authors declare no financial interest or non-financial interest in the subject matter or materials discussed in this manuscript. SK is CEO, founding director and shareholder of Hado Therapeutics Ltd (Registered in the UK: 12240559).
